Skin test for Blomia tropicalis dust mite allergy
Part of Immune system & allergy clinical trials.
This study tests a new skin-prick test for allergy to Blomia tropicalis, a common dust mite in certain areas. It aims to see if the test works well and is safe, and you may join if you have a known mite allergy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 64 years old.
- You have a history of allergy to Blomia tropicalis (a type of dust mite) causing symptoms like runny nose, sneezing, or asthma.
- You have had a positive skin-prick test or blood test for this mite.
- You are not pregnant or breastfeeding, and if you could become pregnant, you agree to use effective birth control during the study.
- You have not had allergy shots (immunotherapy) for dust mites in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an under-the-tongue tablet for people with dust mite allergies causing moderate to severe nasal symptoms or mild-to-moderate asthma. The goal is to see if it improves symptoms and can replace or reduce the need for allergy medicines.
This trial tests a dust-mite allergy extract (“allergy shots”) to see if it safely reduces symptoms from dust-mite–driven hay fever (rhinitis/rhinoconjunctivitis), and possibly asthma symptoms. If you qualify, it may help your immune system tolerate dust mites better over time.
This study uses a small microneedle patch to collect skin-related samples to help predict how well allergy immunotherapy may work. It includes people with house dust mite allergy and also a healthy control group, so researchers can compare biomarker results.
This trial tests allergy drops placed under the tongue to treat allergic rhinitis caused by house dust mites. It aims to see if the drops can safely reduce symptoms like sneezing and stuffy nose.
This Phase 3 study tests whether dust-mite allergy treatment (likely allergy shots) can reduce allergy symptoms and improve safety. It focuses on people whose nose/eye allergy is triggered by house dust mites and who may also have controlled asthma.
This Phase 3 study tests Beltavac®, a treatment aimed at dust mite allergies, to see if it can improve persistent nasal allergy symptoms and help people whose asthma is also affected. You may be a good match if you have confirmed dust mite sensitization and ongoing moderate-to-severe symptoms.
Hear when a new Allergic Reactions trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.